Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Non-Current Assets (2021 - 2025)

Stoke Therapeutics has reported Non-Current Assets over the past 5 years, most recently at $112.7 million for Q4 2025.

  • For Q4 2025, Non-Current Assets rose 190.56% year-over-year to $112.7 million; the TTM value through Dec 2025 reached $346.3 million, up 242.23%, while the annual FY2025 figure was $112.7 million, 190.56% up from the prior year.
  • Non-Current Assets for Q4 2025 was $112.7 million at Stoke Therapeutics, up from $87.8 million in the prior quarter.
  • Over five years, Non-Current Assets peaked at $114.5 million in Q2 2025 and troughed at $9.6 million in Q4 2021.
  • A 5-year average of $32.3 million and a median of $12.3 million in 2022 define the central range for Non-Current Assets.
  • Biggest five-year swings in Non-Current Assets: fell 24.22% in 2023 and later soared 964.18% in 2025.
  • Year by year, Non-Current Assets stood at $9.6 million in 2021, then rose by 24.36% to $12.0 million in 2022, then rose by 8.39% to $13.0 million in 2023, then skyrocketed by 198.38% to $38.8 million in 2024, then surged by 190.56% to $112.7 million in 2025.
  • Business Quant data shows Non-Current Assets for STOK at $112.7 million in Q4 2025, $87.8 million in Q3 2025, and $114.5 million in Q2 2025.